A Review on the Use of Moxifloxacin in Multidrug Resistant Tuberculosis

Praveen D, Priya Rajam Vivean S and Shanmuga Priya J

Genes Review, 2015, vol. 1, issue 2, 33-36

Abstract: The first line anti-tuberculosis drugs have shown an increasing prevalence of resistance. The higher incidence of TB has led to stronger requirements of other therapies apart from the World Health Organisation recommended Directly Observed Therapy in Short course (DOTS). New drugs highly effective against Mycobacterium tuberculosis (MTB) could enhance the treatment of cases with resistance to first line drugs (isoniazid and rifampicin) and may curtail the extent of present regular regimes. Fluoroquinolones are reasonably effective against Mycobacterium tuberculosis (MTB). They have been used as alternative for some present first-line drugs such as Isoniazid, and have been efficient even in Multi Drug Resistant Tuberculosis. These efforts must be further enhanced to ensure ultimate success in discovering, developing, and delivering drastically improved therapies for tuberculosis patients.

Keywords: Tuberculosis; Moxifloxacin; Multidrug resistance; First line drugs; Fluroquinolones; Mycobacterium (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://archive.conscientiabeam.com/index.php/103/article/view/1758/2441 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pkp:genrev:v:1:y:2015:i:2:p:33-36:id:1758

Access Statistics for this article

More articles in Genes Review from Conscientia Beam
Bibliographic data for series maintained by Dim Michael ().